Compare Repligen Corporation Common Stock (RGEN) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Snowflake Inc — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Snowflake Inc trades at $330.2 (market cap $126.22B). The key difference: Snowflake Inc is far larger — about 11.3× Repligen Corporation Common Stock's market cap, and Snowflake Inc is more actively traded (4,112,138 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Snowflake Inc for 53 Days on average.
| RGEN | SNOW | |
|---|---|---|
Market Cap | $11.14B | $126.22B |
Volume | 1,259,263 | 4,112,138 |
Sector | Health | Technology |
52-Week High | $194.57 | $368.89 |
52-Week Low | $102.87 | $121.11 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $11.02B | $126.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Snowflake (SNOW) trades at $335.08, down 7.02% amid market volatility, but maintains strong analyst support with 81% buy ratings and a $418.03 consensus target. The company shows robust revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a -20.07% net margin. Recent technical indicators are bullish on moving averages, while oscillators remain neutral. Key developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath.
Outlook remains positive given strong revenue trajectory and analyst confidence, but risks include persistent losses, high valuation multiples (P/S 22.66), and competitive pressures. The stock offers growth potential if profitability improves, yet investors must weigh execution risks against long-term AI data cloud opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
